Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9506347rdf:typepubmed:Citationlld:pubmed
pubmed-article:9506347lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C1518419lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0817096lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0282461lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0308269lld:lifeskim
pubmed-article:9506347lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:9506347pubmed:issue6lld:pubmed
pubmed-article:9506347pubmed:dateCreated1998-3-25lld:pubmed
pubmed-article:9506347pubmed:abstractTextA three-arm Phase III randomized trial was performed to compare response rates, time to local or distant progression, and survival for patients with unresectable (Stage IIIA or IIIB) nonsmall cell lung carcinoma treated with standard fractionated thoracic radiotherapy (SFTRT) versus accelerated hyperfractionated thoracic radiotherapy (AHTRT) with or without combination etoposide and cisplatin chemotherapy.lld:pubmed
pubmed-article:9506347pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:languageenglld:pubmed
pubmed-article:9506347pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9506347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9506347pubmed:statusMEDLINElld:pubmed
pubmed-article:9506347pubmed:monthMarlld:pubmed
pubmed-article:9506347pubmed:issn0008-543Xlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:McGinnisW LWLlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:CreaganE TETlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:AhujaR KRKlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:JohnsonP APAlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:BonnetJ CJClld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:SloanJ AJAlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:ShawE GEGlld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:MailliardJ...lld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:MarschkeR...lld:pubmed
pubmed-article:9506347pubmed:authorpubmed-author:StellaP JPJlld:pubmed
pubmed-article:9506347pubmed:issnTypePrintlld:pubmed
pubmed-article:9506347pubmed:day15lld:pubmed
pubmed-article:9506347pubmed:volume82lld:pubmed
pubmed-article:9506347pubmed:ownerNLMlld:pubmed
pubmed-article:9506347pubmed:authorsCompleteYlld:pubmed
pubmed-article:9506347pubmed:pagination1037-48lld:pubmed
pubmed-article:9506347pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:meshHeadingpubmed-meshheading:9506347-...lld:pubmed
pubmed-article:9506347pubmed:year1998lld:pubmed
pubmed-article:9506347pubmed:articleTitleThe possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.lld:pubmed
pubmed-article:9506347pubmed:affiliationMayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.lld:pubmed
pubmed-article:9506347pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9506347pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9506347pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9506347pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:9506347pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:9506347pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9506347lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9506347lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9506347lld:pubmed